Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life.
about
Treatment and prophylaxis of invasive candidiasisFluconazole pharmacokinetics and safety in premature infantsClinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infantsPharmacokinetics of an elevated dosage of micafungin in premature neonates.Population pharmacokinetics of fluconazole in young infants.Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Administration of fluconazole in children below 1 year of age.The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyPractice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.Antifungal susceptibility testing: practical aspects and current challenges.Safety and tolerability of fluconazole in children.Population pharmacokinetics of amphotericin B lipid complex in neonates.Toxicokinetics in infants and children in relation to the ADI and TDI.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Management of neonatal candidiasis. Neonatal Candidiasis Study GroupDuration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials.Antibiotics and antifungals in neonatal intensive care units: a review.Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Invasive fungal infections in the ICU.Fluconazole prophylaxis in high-risk neonates.Prediction of drug clearance in children 3 months and younger: an allometric approach.Safety of fluconazole in paediatrics: a systematic reviewInvasive fungal infections in newborns and current management strategies.Neonatal liver abscesses associated with candidemia: three cases and review of literature.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Antifungal agents in neonatal systemic candidiasisExternal Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries.Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.
P2860
Q27001567-9EE48E2A-3B0F-4917-854A-11598BFC8F9CQ27014816-E3E71499-F94B-4230-9837-6C7E312D75D6Q30433993-6F79E3B9-A2DB-4202-915A-72005905A9B7Q30435365-34D641C7-F118-426F-AD46-003EC781F53EQ30436332-BE1EE4AB-1EAF-459E-881B-5885632727DAQ30439710-B0E7112C-A48C-4EF9-B2BB-FE413CD747C3Q30792309-E4DCF0CE-C7B5-49DA-87DE-D9E786CE2AADQ30844731-FBBAC632-D137-490B-BED9-D147FCD9E45BQ33680336-381ECCD5-6DEB-4492-A5EF-9B7740B7CC18Q33788619-FEE44D58-7A4E-4BAB-9BEC-1AC876D77C28Q33827819-AA03203A-F536-4F9F-934B-49D85068D1C7Q33894467-8909AEBD-FD2E-4DDC-8393-BF48A8AD1A29Q33975757-C55701D9-9CFB-4353-A4F1-036DEDCE39E7Q33977410-87F9A632-EBFE-4087-84CC-A28EA23FC9EEQ34228332-CB20C37C-8B34-486F-8F9D-21DC24EDB70FQ34469520-C649D71B-9A0D-4627-94D2-0AE54E85966DQ34505582-F7424E7E-E47C-476D-98B7-B2FB8368A96DQ34680771-4BB8240C-3124-470F-949F-53BCD150E4B1Q36062895-4E660D17-9DC1-44B2-B303-192D25D61FA1Q36740036-04A9639A-96F2-4D32-97F6-D072D01E59DFQ36822025-671A0DAF-7205-42F6-B480-40B05F3EFEADQ36948094-8F4628D2-16B2-480E-A9C5-77D1DE5581D7Q37203784-0F10CFC4-86B1-40FB-95A9-6F543BA13A8FQ37521422-44DF2DAB-4874-492A-A9CE-A0F23854244FQ37643057-144BBA00-CF7C-4B03-A079-817C8BB88458Q37664330-E0B935E1-3299-4E5A-BC00-AB38FB2AB463Q37854677-75382A54-F75D-4EB1-A29F-A7DBD3EBA21DQ38074608-574AF249-62B9-4C18-B9BA-4CB16886993BQ38119554-3FAE7191-BFF2-4CFE-BF65-C5F5EEB35C21Q38131856-92F12AC1-7A5F-40E6-9A9F-F38FCF9F3568Q38193337-5CF0C93B-C7B8-49DE-B4B9-5B43481BD94DQ38215682-EA99CDB9-BD9A-406B-9FF9-4EACA96CD577Q38816614-9F588460-4CB6-4902-9775-918B538545B7Q39779942-B5E2F3F6-A81F-4DBF-B3F3-759C05004545Q46406734-07E8B2A8-A3C4-4968-9688-973B3083B064Q48163160-09C433C0-13D5-41D2-AD5A-0E548F6B6559Q50593909-A8B845ED-3505-4276-AA1D-CEA1FD49AB83Q54250407-C514B31F-9BCF-4BB8-8D49-C7A11DAF8481
P2860
Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@en
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@nl
type
label
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@en
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@nl
prefLabel
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@en
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@nl
P356
P1476
Pharmacokinetics of fluconazol ...... g the first two weeks of life.
@en
P2093
P304
P356
10.1038/CLPT.1993.147
P407
P50
P577
1993-09-01T00:00:00Z